TREATMENT FOR CANCER HAVING RESISTANCE TO RADIOTHERAPY

PROBLEM TO BE SOLVED: To provide a means suppressing relapse and metastasis and further increasing the effect in radiotherapy of radiation resistant cancer except hypoxic state, by irradiating radiation in the presence of 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole. SOLUTION: I...

Full description

Saved in:
Bibliographic Details
Main Authors TOMIYAMA SUSUMU, FUJIWARA HIROMITSU, KUBOTA NOBUO, SHIRAISHI KOZUE, YAHIRO TOMOAKI
Format Patent
LanguageEnglish
Published 20.12.2007
Subjects
CHEMISTRY
ELECTROTHERAPY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MAGNETOTHERAPY
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
RADIATION THERAPY
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
ULTRASOUND THERAPY
Online AccessGet full text

Cover

More Information
Summary:PROBLEM TO BE SOLVED: To provide a means suppressing relapse and metastasis and further increasing the effect in radiotherapy of radiation resistant cancer except hypoxic state, by irradiating radiation in the presence of 1-(1-hydroxymethyl-2,3-dihydroxypropyl)oxymethyl-2-nitroimidazole. SOLUTION: In radiotherapy of cancer having radiation resistance, a radiation sensitizer of chemical formula 1 is used to sensitize and treat. The compound of chemical formula 1 of 10-400 mg is administered based on 1 kg body weight of animal or human and radiation is irradiated. The radiation resistant cancer is preferably lung adenocarcinoma. Fractionated irradiation therapy comprising administering 10-400 mg compound of formula 1 per 1 kg body weight to the animal or the human and then repeating 5-40 times irradiation of 1-10 Gy is preferable. COPYRIGHT: (C)2008,JPO&INPIT
Bibliography:Application Number: JP20060159253